Complete Primary Pathological Response Following Neoadjuvant Treatment and Radical Resection for Pancreatic Ductal Adenocarcinoma

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Jan 26

PMID 38275893

Authors

Kai Tai Derek Yeung

Joseph Doyle

Sacheen Kumar

Katharine Aitken

Diana Tait

David Cunningham

Long R Jiao

Ricky Harminder Bhogal

Affiliations

Soon will be listed here.

Abstract

Introduction: Neoadjuvant treatment (NAT) for borderline (BD) or locally advanced (LA) primary pancreatic cancer (PDAC) is now a widely adopted approach. We present a case series of patients who have achieved a complete pathological response of the primary tumour on final histology following neoadjuvant chemotherapy +/- chemoradiation and radical surgery.

Methods: Patients who underwent radical pancreatic resection following neoadjuvant treatment between March 2006 and March 2023 at a single institution were identified by retrospective case note review of a prospectively maintained database.

Results: Ten patients were identified to have a complete primary pathological response (ypT0) on postoperative histology. Before treatment, five patients were considered BD and five were LA according to National Comprehensive Cancer Network guidelines. All patients underwent staging Computed Tomography (CT) and nine underwent Fluorodeoxyglucose Positron Emission Tomography (FDG-PET/CT) imaging, with a mean maximum standardized uptake value (SUVmax) of the primary lesion at 6.14 ± 1.98 units. All patients received neoadjuvant chemotherapy, and eight received further chemoradiotherapy prior to resection. Mean pre- and post-neoadjuvant treatment serum Ca19-9 was 148.0 ± 146.3 IU/L and 18.0 ± 18.7 IU/L, respectively ( = 0.01). The mean duration of NAT was 5.6 ± 1.7 months. The mean time from completion of NAT to surgery was 13.1 ± 8.3 weeks. The mean lymph node yield was 21.1 ± 10.4 nodes, with one patient found to have 1 lymph node involved. All resections were reported to be R0. The mean length of stay was 11.8 ± 6.2 days. At the time of analysis, one death was reported at 35 months postoperatively. Two cases of recurrence were reported at 16 months (surgical bed) and 33 months (pulmonary). All other patients remain alive and under active surveillance. The current overall survival is 26.6 ± 20.7 months and counting.

Conclusions: Complete primary pathological response is uncommon but possible following neoadjuvant treatment in patients with PDAC. Further work to identify the common denominator within this unique cohort may lead to advances in the therapeutic approach and offer hope for patients diagnosed with borderline or locally advanced pancreatic ductal adenocarcinoma.

References

Cloyd J, Chen H, Wang X, Tzeng C, Kim M, Aloia T . Chemotherapy Versus Chemoradiation as Preoperative Therapy for Resectable Pancreatic Ductal Adenocarcinoma: A Propensity Score Adjusted Analysis. Pancreas. 2019; 48(2):216-222. DOI: 10.1097/MPA.0000000000001231. View

Pietrasz D, Turrini O, Vendrely V, Simon J, Hentic O, Coriat R . How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRENCH Multicentric Cohort. Ann Surg Oncol. 2018; 26(1):109-117. DOI: 10.1245/s10434-018-6931-6. View

Cloyd J, Wang H, Egger M, Tzeng C, Prakash L, Maitra A . Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2017; 152(11):1048-1056. PMC: 5710421. DOI: 10.1001/jamasurg.2017.2227. View

Gemenetzis G, Groot V, Blair A, Laheru D, Zheng L, Narang A . Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection. Ann Surg. 2018; 270(2):340-347. PMC: 6985003. DOI: 10.1097/SLA.0000000000002753. View

Hue J, Sugumar K, Bingmer K, Ammori J, Winter J, Hardacre J . Neoadjuvant chemoradiation may be associated with improved pathologic response in pancreatic cancer. Am J Surg. 2020; 221(3):500-504. DOI: 10.1016/j.amjsurg.2020.11.035. View

Zhou Y, Liao S, You J . Pathological complete response after neoadjuvant therapy for pancreatic ductal adenocarcinoma does not equal cure. ANZ J Surg. 2021; 91(5):E254-E259. DOI: 10.1111/ans.16665. View

He J, Blair A, Groot V, Javed A, Burkhart R, Gemenetzis G . Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer?. Ann Surg. 2018; 268(1):1-8. PMC: 6178802. DOI: 10.1097/SLA.0000000000002672. View

Leonhardt C, Pils D, Qadan M, Jomrich G, Assawasirisin C, Klaiber U . The Revised R Status is an Independent Predictor of Postresection Survival in Pancreatic Cancer After Neoadjuvant Treatment. Ann Surg. 2023; 279(2):314-322. PMC: 10782940. DOI: 10.1097/SLA.0000000000005874. View

Murphy J, Wo J, Ryan D, Clark J, Jiang W, Yeap B . Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019; 5(7):1020-1027. PMC: 6547247. DOI: 10.1001/jamaoncol.2019.0892. View

10.

Dindo D, Demartines N, Clavien P . Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004; 240(2):205-13. PMC: 1360123. DOI: 10.1097/01.sla.0000133083.54934.ae. View

11.

Rashid O, Pimiento J, Gamenthaler A, Nguyen P, Ha T, Hutchinson T . Outcomes of a Clinical Pathway for Borderline Resectable Pancreatic Cancer. Ann Surg Oncol. 2015; 23(4):1371-9. DOI: 10.1245/s10434-015-5006-1. View

12.

Sell N, Lee G, Fernandez-Del Castillo C, Ferrone C, Warshaw A, Hong T . Evaluation of Pathologic Response on Overall Survival After Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Pancreas. 2020; 49(7):897-903. PMC: 7368813. DOI: 10.1097/MPA.0000000000001590. View

13.

Conroy T, Hammel P, Hebbar M, Abdelghani M, Wei A, Raoul J . FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med. 2018; 379(25):2395-2406. DOI: 10.1056/NEJMoa1809775. View

14.

Tempero M . NCCN Guidelines Updates: Pancreatic Cancer. J Natl Compr Canc Netw. 2019; 17(5.5):603-605. DOI: 10.6004/jnccn.2019.5007. View

15.

Rose J, Rocha F, Alseidi A, Biehl T, Moonka R, Ryan J . Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival. Ann Surg Oncol. 2014; 21(5):1530-7. DOI: 10.1245/s10434-014-3486-z. View

16.

De la Pinta C . Radiomics in pancreatic cancer for oncologist: Present and future. Hepatobiliary Pancreat Dis Int. 2021; 21(4):356-361. DOI: 10.1016/j.hbpd.2021.12.006. View

17.

Versteijne E, van Dam J, Suker M, Janssen Q, Groothuis K, Akkermans-Vogelaar J . Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial. J Clin Oncol. 2022; 40(11):1220-1230. DOI: 10.1200/JCO.21.02233. View

18.

Liu H, DAlesio M, AlMasri S, Hammad A, Desilva A, Lebowitz S . No survival benefit with suboptimal CA19-9 response: defining effective neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer. HPB (Oxford). 2023; 25(5):521-532. PMC: 11232030. DOI: 10.1016/j.hpb.2023.01.016. View

19.

Campos-Lobato L, Stocchi L, da Luz Moreira A, Geisler D, Dietz D, Lavery I . Pathologic complete response after neoadjuvant treatment for rectal cancer decreases distant recurrence and could eradicate local recurrence. Ann Surg Oncol. 2011; 18(6):1590-8. DOI: 10.1245/s10434-010-1506-1. View

20.

Cloyd J, Ejaz A, Shen C, Dillhoff M, Williams T, Noonan A . Pathologic complete response following neoadjuvant therapy for pancreatic ductal adenocarcinoma: defining the incidence, predictors, and outcomes. HPB (Oxford). 2020; 22(11):1569-1576. DOI: 10.1016/j.hpb.2020.01.013. View